Skip to content

LE as a Marker for Periprosthetic Joint Infection

Electrochemical Test of Leukocyte Esterase as a Marker for Periprosthetic Joint Infection

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05440032
Enrollment
160
Registered
2022-06-30
Start date
2023-12-07
Completion date
2024-03-31
Last updated
2024-01-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prosthetic-joint Infection

Brief summary

Testing and comparison of a novel point-of-care electrochemical assay to detect and help diagnose periprosthetic joint infection on the hip and knee to the standard of care test

Detailed description

The primary objective of this study is to assess the equivalence of a semi-quantitative electrochemical leukocyte esterase test system and off-label use of the Roche Chemstrip leukocyte esterase (LE) test for the diagnosis of periprosthetic joint infection (PJI) in synovial fluid from hip and knee joints. In this study, the qualitative outcome of each of the two methodologies for detecting leukocyte esterase enzyme will be compared. The hypothesis of this study is that the two tests will demonstrate equivalence. The leukocyte esterase enzyme level will also be compared to synovial white blood cell count, which will be considered as a secondary reference.

Interventions

DIAGNOSTIC_TESTSemi-quantitative electrochemical leukocyte esterse test strip

Electrochemical assay to detect level of leukocyte esterase in sample

DIAGNOSTIC_TESTRoche Chemstrip

Urinalysis chemstrip

Sponsors

Center for Innovation and Research Organization
Lead SponsorNETWORK

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Age greater than 18 years 2. Willing and able to sign the informed consent document 3. Subjects presenting with presumed aseptic failure of a prosthetic joint and expected to undergo revision arthroplasty, or subjects presenting with presumed PJI and expected to undergo either DAIR or radical implant resection, and subjects being investigated for PJI having joint aspiration outside of the operating room who may or may not require surgical intervention.

Exclusion criteria

1. Subjects with known active crystalline deposition disease (e.g. gout) 2. Subjects with adverse local tissue reaction (ALTR) as a result of corrosion of components or metal-on-metal bearing surface in the hip 3. Subjects with active inflammatory arthropathy (e.g. rheumatoid arthritis) 4. Subjects undergoing a second-stage re-implantation procedure for PJI 5. Subjects in which standard of care assessments, at a minimum serology (ESR and CRP) and synovial fluid analysis (synovial WBC count, neutrophil percentage, and culture), cannot be performed. 6. Subjects in whom there is an insufficient amount of synovial fluid to perform the required investigational tests.

Design outcomes

Primary

MeasureTime frame
Qualitative agreement (Positive, Intermediate, or Negative) between the semi-quantitative electrochemical LE test and Roche Chemstrip® LE test (Negative, Trace, 1+, or 2+)Within one hour of fluid aspiration

Secondary

MeasureTime frame
Correlation of leukocyte esterase and synovial white blood cell countWithin 30 days of surgery

Countries

United States

Contacts

Primary ContactTiffany Morrison
tiffany@parvizisurgical.com717-856-1202

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026